A crossover comparison of urinary albumin excretion as a new surrogate marker for cardiovascular disease among 4 types of calcium channel blockers

International Journal of Cardiology

Volumn 166, Issue 2, 2013, Pages 448-452

  Konoshita, Tadashi ^a   Makino, Yasukazu ^a   Kimura, Tomoko ^a   Fujii, Miki ^a   Morikawa, Norihiro ^a   Wakahara, Shigeyuki ^a   Arakawa, Kenichiro ^a   Inoki, Isao ^a   Nakamura, Hiroyuki ^a   Miyamori, Isamu ^a  

^a University of Fukui   (Japan)

Author keywords

Albuminuria; Calcium channel blocker; L type calcium channel; N type calcium channel; Renin angiotensin system; T type calcium channel

Indexed keywords

ALBUMIN; AMLODIPINE; ANGIOTENSIN I; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CALCIUM CHANNEL T TYPE; CILNIDIPINE; EFONIDIPINE; NIFEDIPINE;

ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG HALF LIFE; FEMALE; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; PROTECTION; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

AGED; AGED, 80 AND OVER; ALBUMINURIA; BIOLOGICAL MARKERS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; DIHYDROPYRIDINES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NIFEDIPINE;

EID: 84878016015     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.10.133     Document Type: Article

References (43)

1. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 39 2002 S1 S266
2. M.J. Sarnak, A.S. Levey, and A.C. Schoolwerth Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention Circulation 108 2003 2154 2169
3. R. Kalaitzidis, and G. Bakris Pathogenesis and treatment of microalbuminuria in patients with diabetes: the road ahead J Clin Hypertens (Greenwich) 11 2009 636 643
4. P. Ruggenenti, A. Perna, and G. Remuzzi Retarding progression of chronic renal disease: the neglected issue of residual proteinuria Kidney Int 63 2003 2254 2261
5. D. de Zeeuw, G. Remuzzi, and H.H. Parving Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy Circulation 110 2004 921 927
6. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators Lancet 355 2000 253 259
7. B.M. Brenner, M.E. Cooper, and D. de Zeeuw Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
8. G.L. Bakris, M.R. Weir, V. DeQuattro, and F.G. McMahon Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy Kidney Int 54 1998 1283 1289
9. P. Corvol, F. Soubrier, and X. Jeunemaitre Molecular genetics of the renin-angiotensin-aldosterone system in human hypertension Pathol Biol (Paris) 45 1997 229 239
10. V. Dzau The cardiovascular continuum and renin-angiotensin-aldosterone system blockade J Hypertens Suppl 23 2005 S9 S17
11. S. Wakahara, T. Konoshita, and S. Mizuno Synergistic expression of angiotensin-converting enzyme (ACE) and ACE2 in human renal tissue and confounding effects of hypertension on the ACE to ACE2 ratio Endocrinology 148 2007 2453 2457
12. T. Konoshita, S. Wakahara, and S. Mizuno Tissue gene expression of renin-angiotensin system in human type 2 diabetic nephropathy Diabetes Care 29 2006 848 852
13. T. Konoshita, S. Germain, J. Philippe, P. Corvol, and F. Pinet Evidence that renal and chorionic tissues contain similar nuclear binding proteins that recognize the human renin promoter Kidney Int 50 1996 1515 1524
14. S. Germain, T. Konoshita, J. Philippe, P. Corvol, and F. Pinet Transcriptional induction of the human renin gene by cyclic AMP requires cyclic AMP response element-binding protein (CREB) and a factor binding a pituitary-specific trans-acting factor (Pit-1) motif Biochem J 316 1996 107 113
15. S. Fuchs, J. Philippe, P. Corvol, and F. Pinet Implication of Ref-1 in the repression of renin gene transcription by intracellular calcium J Hypertens 21 2003 327 335
16. T. Konoshita, Y. Makino, and S. Wakahara Candidate cis-elements for human renin gene expression in the promoter region J Cell Biochem 93 2004 327 336
17. T. Konoshita, S. Fuchs, Y. Makino, S. Wakahara, and I. Miyamori A proximal direct repeat motif characterized as a negative regulatory element in the human renin gene J Cell Biochem 102 2007 1043 1050
18. 2 + channels Annu Rev Cell Dev Biol 16 2000 521 555
19. E.A. Ertel, K.P. Campbell, and M.M. Harpold Nomenclature of voltage-gated calcium channels Neuron 25 2000 533 535
20. A. Takahara Cilnidipine: a new generation ca channel blocker with inhibitory action on sympathetic neurotransmitter release Cardiovasc Ther 27 2009 124 139
21. KDOQI Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease Am J Kidney Dis 49 2007 S12 S154
22. Y. Konno, and K. Kimura Vasodilatory effect of cilnidipine, an L-type and N-type calcium channel blocker, on rat kidney glomerular arterioles Int Heart J 49 2008 723 732
23. 2 + channel subtypes and pharmacology in the kidney Circ Res 100 2007 342 353
24. N. Hasebe, and K. Kikuchi Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study J Hypertens 23 2005 445 453
25. K. Katayama, S. Nomura, H. Ishikawa, T. Murata, S. Koyabu, and T. Nakano Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria Kidney Int 70 2006 151 156
26. T. Fujisawa, H. Ikegami, and S. Noso Renoprotective effect of N-type Ca channel blockade in diabetic nephropathy J Diabetes Complications 21 2007 252 257
27. T. Fujita, K. Ando, and H. Nishimura Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease Kidney Int 72 2007 1543 1549
28. S. Morimoto, Y. Yano, K. Maki, and T. Iwasaka Renal and vascular protective effects of cilnidipine in patients with essential hypertension J Hypertens 25 2007 2178 2183
29. K. Kario Morning surge in blood pressure and cardiovascular risk: evidence and perspectives Hypertension 56 2010 765 773
30. T. Konda, A. Enomoto, J. Matsushita, A. Takahara, and T. Moriyama The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome Nephron Physiol 101 2005 1 13
31. T. Konda, A. Enomoto, and S. Aritomi Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/Izm Am J Nephrol 30 2009 155 161
32. T. Konoshita, Y. Makino, and T. Kimura A new-generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker J Hypertens 28 2010 2156 2160
33. 2 + channels in evoked release of norepinephrine from sympathetic neurons Science 239 1988 57 61
34. 2 + current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurones Br J Pharmacol 122 1997 37 42
35. A. Takahara, H. Dohmoto, H. Hisa, S. Satoh, and R. Yoshimoto Cilnidipine attenuates renal nerve stimulation-induced renal vasoconstriction and antinatriuresis in anesthetized dogs Jpn J Pharmacol 75 1997 27 32
36. Y.Y. Fan, M. Kohno, and D. Nakano Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte J Hypertens 28 2010 1034 1043
37. S. Somekawa, K. Imagawa, and N. Naya Regulation of aldosterone and cortisol production by the transcriptional repressor neuron restrictive silencer factor Endocrinology 150 2009 3110 3117
38. J.D. Dietz, S. Du, and C.W. Bolten A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity Hypertension 51 2008 742 748
39. T. Sugiura, E. Imai, T. Moriyama, M. Horio, and M. Hori Calcium channel blockers inhibit proliferation and matrix production in rat mesangial cells: possible mechanism of suppression of AP-1 and CREB activities Nephron 85 2000 71 80
40. A. Matsumori, Y. Nunokawa, and S. Sasayama Nifedipine inhibits activation of transcription factor NF-kappaB Life Sci 67 2000 2655 2661
41. H. Haller, S. Ito, and J.L. Izzo Jr. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes N Engl J Med 364 2011 907 917
42. K.A. Griffin, M. Picken, G.L. Bakris, and A.K. Bidani Comparative effects of selective T- and L-type calcium channel blockers in the remnant kidney model Hypertension 37 2001 1268 1272
43. T. Konoshita, N. Kato, and S. Fuchs Genetic variant of the renin-angiotensin system and diabetes influences blood pressure response to angiotensin receptor blockers Diabetes Care 32 2009 1485 1490